PROGRESS

In The Management Of Cystic Fibrosis



creon®
pancreatin

RIGHT ON TARGET – RIGHT FROM THE START

Prescribing Information – Presentation: Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

Contra-indications, Warnings, etc: Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

duphar Further information is available from:
Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281.

CRAd/PEI/1/89

Making sure Ventolin gets through to the younger generation



VENTODISKS

(Salbutamol BP)

Ventodisks (Salbutamol BP). **Abridged Prescribing Information** (Please refer to full data sheet before prescribing.) **Uses:** Treatment and prophylaxis of acute and chronic bronchospasm. **Dosage and administration:** *Adults:* 400 micrograms as single dose or three to four times daily. *Children:* 200 micrograms as single dose or three to four times daily. **Contra-indications:** Threatened abortion during first or second trimester. Hypersensitivity. **Precautions:** If previously effective dose lasts less than three hours, seek medical advice. Caution in patients with thyrotoxicosis. Avoid use with non-selective beta-blockers. Hypokalaemia may occur, particularly in acute severe asthma. It may be potentiated by xanthine derivatives, steroids, diuretics and hypoxia. Serum potassium levels should be monitored in such situations. *Pregnancy:* Avoid unnecessary use during early pregnancy. Only consider if expected benefit outweighs possible risks. *Lactation:* Salbutamol likely to be secreted in breast milk. Effect on neonate unknown. Balance risks against benefits. **Side effects:** Mild tremor, headache occur rarely. Very rarely — transient muscle cramps and hypersensitivity reactions. Potentially serious hypokalaemia may result from β_2-agonist therapy. Paradoxical bronchospasm could occur – substitute alternative therapy. **Presentation and Basic NHS cost:** Pack of 14 Ventodisks each containing 8 x 200 micrograms Salbutamol BP (as sulphate) — light blue or 8 x 400 micrograms Salbutamol BP (as sulphate) — dark blue, together with a Ventolin Diskhaler. For inhalation. £7·11 and £12·02. Refill pack of 14 x 8 Ventodisks only. 200 micrograms, £6·54; 400 micrograms, £11·45. **Product licence numbers:** Ventodisks 200 micrograms 0045/0134, Ventodisks 400 micrograms 0045/0135.

ALLEN & HANBURYS

Further information is available on request from: Allen & Hanburys Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT
Ventodisks should only be used with a Ventolin Diskhaler. Diskhaler, Ventodisks and Ventolin are trade marks

Bronchitis simplicity





Abbreviated Prescribing Information for ZITHROMAX*
Indications and dosage: Upper and lower respiratory tract infections, skin and soft tissue infections and otitis media: 500mg once daily for 3 days. As an alternative a single dose of 500mg on day 1, then 250mg once daily on days 2 to 5. **Use in the elderly:** Normal adult dosage is recommended. **Use in children:** For dosage recommendations see data sheet. **Administration:** ZITHROMAX should be administered as a single daily dose at least 1 hour before or 2 hours after food. ZITHROMAX oral suspension should be administered to children using the spoon provided. **Contra-indications:** Hypersensitivity to azithromycin or other macrolide antibiotics. Patients receiving ergot derivatives. **Warnings and Precautions:** Moderate or severe renal impairment (creatinine clearance <40ml/min), liver impairment. Pregnancy and lactation: Not recommended. **Drug Interactions:** Antacids, ergot derivatives. Monitor patients on concurrent warfarin, digoxin or cyclosporin. **Side-Effects:** Nausea, abdominal discomfort, vomiting, flatulence, diarrhoea, loose stools, elevation in liver transaminases and reduction in neutrophil counts. **Package quantities and Basic NHS Cost:** 250mg capsule, pack of 6, £14.99 (PL 0057/0335); Powder for Oral Suspension – bottles of 15ml, 22.5ml and 30ml containing ZITHROMAX 200mg/5ml – 15ml bottle (600mg), £7.05; 22.5ml (900mg), £10.35; 30ml (1200mg), £13.80 (PL 0057/0336). Hospital prices are available on request.
Further information on request. Richborough Pharmaceuticals A Division of Pfizer Limited, Sandwich, Kent.
References 1. Foulds G et al. (1990) J Antimicrob Chemother; **25**(Suppl A): 73-82. 2. Hopkins S. (1991) Am J Med; **91**(Suppl 3A): 40S-45S. 3. Data on file, Richborough Pharmaceuticals (Ref PR326).

RICHBOROUGH® PHARMACEUTICALS
A Division of Pfizer Ltd. Sandwich, Kent CT13 9NJ

ZITHROMAX*, the first once-daily, 3 day course for bronchitis, simplifies therapy and assists patient compliance. Sustained high tissue concentrations are achieved by **ZITHROMAX***, so therapy continues for up to seven days after dosing stops.[1]

ZITHROMAX* is effective and well tolerated[2] with a good clinical response in 94% of patients suffering from bronchitis.[3]

NEW
3 days, once-daily
ZITHROMAX*▼
azithromycin
Compliance is built in

*Trademark

70128



A world of difference

More and more patients with uncontrolled epilepsy are able to face the world thanks to the efficacy of SABRIL.

Many have become seizure free for the first time and approximately half can benefit from a > 50% reduction in their seizures.[1]

SABRIL®
VIGABATRIN

Controlling seizures, changing lives

Abridged prescribing Information and reference appear on the following page

Abridged Prescribing Information
SABRIL Tablets
Presentation: White, tablets with a breakline marked SABRIL, each containing 500mg vigabatrin.
Uses: *Indications:* Treatment of epilepsy not controlled by other antiepileptic drugs.
Dosage and Administration: Oral administration once or twice daily added to the patient's current therapeutic regimen.
Adults: Recommended starting dose 2g/day. Increased or decreased in 0.5g or 1.0g increments depending upon clinical response and tolerability. Maximum 4g/day. There is no direct correlation between plasma concentration and efficacy.
Children: The recommended starting dose in children is 40mg/kg/day increasing to 80-100mg/kg/day depending on response. Convenient recommendations in relation to bodyweight are:

Bodyweight:		
	10-15kg	0.5 to 1g/day
	15-30kg	1.0-1.5g/day
	30-50kg	1.5-3g/day
	>50kg	2-4g/day

Infants with West syndrome may require doses of 100mg/kg/day or higher.
Elderly: Consider dose reduction in patients with impaired renal function.
Contra-indications, Precautions, Warnings etc.
Use in pregnancy and lactation: Contra-indicated.
Precautions: Abrupt withdrawal may lead to rebound seizures. Caution in patients with history of psychosis or behavioural problems. Caution in elderly patients, particularly creatinine clearance below 60ml/min. Reduce dose and monitor closely for adverse events.
Warnings: Vigabatrin causes intramyelinic oedema in the brain white matter tracts of animals but there is no evidence of this in man. However, monitor patients for neurological changes. See the full product data sheet.
Effects on driving ability: Drowsiness has been seen and patients should be warned.
Side effects: Are mainly CNS related. Aggression and psychosis have been reported and a previous history of psychosis or a behavioural problem appears to be a predisposing factor. Other reported events: drowsiness and fatigue, dizziness, nervousness, irritability, depression, headache and less commonly confusion, memory disturbance and vision complaints; also weight gain and minor gastrointestinal side-effects. Also in children excitation and agitation. Some patients may experience an increase in seizure frequency with vigabatrin, particularly those with myoclonic seizures. Tests have not revealed evidence of neurotoxicity in humans. Lab data do not indicate renal or hepatic toxicity. Decreases in SGOT and SGPT have been observed. Chronic treatment may lead to a slight decrease in haemoglobin.
Drug Interactions: Are unlikely. A gradual reduction of about 20% in plasma phenytoin concentration has been observed.
No clinically significant interactions with carbamazepine, phenobarbitone or sodium valproate.
Legal Category: POM
Package Quantities: Blister strips of 10 in cartons of 100.
Product Licence Number: PL 4425/0096
NHS Price: £46.00
Date of Preparation: January 1992.
You must refer to the full prescribing information before administering Sabril. Further information including full product data sheet is available from the Licence Holder: Marion Merrell Dow Ltd., Lakeside House, Stockley Park, Uxbridge, Middlesex. UB11 1BE.

Reference:
1. Mumford JP.Br J Clin Pract 1988; 42 (Suppl 61): 7-9

MARION MERRELL DOW LTD.

Trademarks: Marion, Merrell, Dow, Sabril. SAB/AD/0492

WHEN THEY FEEL LIKE THIS ABOUT SWALLOWING THEIR MEDICINE

When children won't or can't tolerate oral pain killers, another course of action is needed.

Alvedon paracetamol suppositories provide a fast, effective alternative.[1,2]

Its antipyretic effect being as rapid as that of oral paracetamol.[1,2]

So when oral treatments are out of the question, choose Alvedon.

TRY ANOTHER ROUTE

Alvedon™

PARACETAMOL SUPPOSITORIES 125 mg

RELIEVES PAIN – REDUCES FEVER

Hepatic necrosis may occur after overdosage. Pharmaceutical Precautions Store below 25°C. Legal Category: P. Package Quantities: Pre-formed plastic strips of 5 x 2 or 5 x 10 suppositories. Product Licence No. 0017/0252. Product Licence Holder: Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH.

REFERENCES: 1. Vernon S. et al. Archives of Disease in Childhood, 1979, 54; 469-479. 2. Maron J.F. & Klein A.C. Current Therapeutic Research, 1976, 20; No 1, 45-52.

Full information is available from:

NOVEX

Alvedon™ Suppositories 125mg

PRESENTATION: White to yellowish white suppositories containing 125mg paracetamol.

USES: For treatment of mild to moderate pain and pyrexia in children. Alvedon suppositories may be especially useful in patients unable to take oral forms of paracetamol eg. post-operatively or with nausea and vomiting.

DOSAGE AND ADMINISTRATION: Children: 1-5 years, 1-2 suppositories.

The dosage should be based on age and weight ie.

1 year (10kg) 1 suppository
5 years (20kg) 2 suppositories

These doses may be repeated up to 4 times daily.

CONTRA-INDICATIONS, WARNINGS, ETC:

Contra-indications:
Hypersensitivity to paracetamol.

Precautions:
Paracetamol should be given with care to patients with impaired kidney or liver function.

Interactions:
Drugs which induce hepatic microsomal enzymes such as alcohol, barbiturates and other anticonvulsants may increase the hepatotoxicity of paracetamol particularly after overdosage.

Side-effects:
Side-effects at therapeutic doses are rare. Isolated cases of liver damage and allergic reactions such as skin rash have been reported.

Redness of the mucous membrane of the rectum and minor local vascular changes have been reported after the use of Alvedon suppositories. Hepatic necrosis may occur after overdosage. (See below).

Pregnancy and Lactation:
Not applicable.

PHARMACEUTICAL PRECAUTIONS: Store below 25°C.

LEGAL CATEGORY: P

PACKAGE QUANTITIES: 10 strips each containing 5 suppositories or 2 strips each containing 5 suppositories.

FURTHER INFORMATION: **Treatment of overdosage:** Clinical symptoms of liver damage are manifested usually after 48 hours. Overdosage results in saturation of the conjugation capacity of the liver and irreversible binding of a reactive intermediate metabolite in the hepatocytes. N-acetylcysteine intravenously or L-methionine orally protects the liver if adminstered within 10-12 hours of ingesting an overdose.

PRODUCT LICENCE NO: 0017/0250.

PRODUCT LICENCE HOLDER: Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH.

DATE OF PREPARATION: June 1991.

Alvedon suppositories are marketed and distributed by
NOVEX PHARMA, a division of NOVEX PHARMA LTD.,
Henley-on-Thames, Oxon, RG9 1EL

*Alvedon trademark applied for by AB Astra.

While you're trying to make it better, make it bearable.



Zofran
ondansetron

Prescribing information: Uses Nausea and vomiting due to chemotherapy or radiotherapy. **Dosage** *Emetogenic chemotherapy and radiotherapy:* Either, 8mg i.v. as a slow injection immediately before treatment, or 8mg orally 1 to 2 hours before treatment, followed by 8mg orally twelve-hourly. To protect against delayed emesis, Zofran should be continued orally, 8mg twice daily for up to 5 days. *Highly emetogenic chemotherapy:* A single dose of 8mg i.v. as a slow injection immediately before chemotherapy, followed by 8mg orally twice daily for up to 5 days to protect against delayed emesis. The efficacy of Zofran over the first 24 hours of highly emetogenic chemotherapy may be enhanced by the addition of a single i.v. dose of 20mg dexamethasone immediately before treatment. Alternatively, higher doses of Zofran may be beneficial, up to 32mg depending on the severity of the emetogenic challenge. *Children:* A single i.v. dose of 5mg/m² immediately before chemotherapy, followed by 4mg orally twelve-hourly for up to 5 days. *Elderly and patients with renal impairment:* No alteration of dosage, dosing frequency or route of administration is required over 65 years or with renal impairment. *Patients with hepatic impairment:* In patients with moderate or severe hepatic impairment, a total daily dosage of 8mg should not be exceeded. **Contra-indications** Hypersensitivity to components. **Precautions** Pregnancy or lactation. **Side effects** Headache, constipation, a warm or flushing sensation in the head or epigastrium. Occasional transient rises in aminotransferases. Rare, immediate hypersensitivity reactions (see data sheet). **Presentations** Zofran Injection ampoules containing 4mg ondansetron in 2ml aqueous solution or 8mg ondansetron in 4ml aqueous solution (Product licence number 0004/0375, 4mg x 5 ampoules £52·50; 8mg x 5 ampoules £75). Zofran 4mg Tablets each containing 4mg ondansetron (Product licence number 0004/0376, 4mg x 30 tablets £187·50). Zofran 8mg Tablets each containing 8mg ondansetron (Product licence number 0004/0377, 8mg x 10 tablets £90). **Product licence holder** Glaxo Operations U.K. Limited, Greenford, Middlesex UB6 0HE. Zofran is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Tel: 081-990 9444.

European Journal of
Pediatrics
Incorporating
Acta Paediatrica Belgica
and
Helvetica Paediatrica Acta

Volume 150 No. 12 1991

Indexed in *Current Contents*

Springer International

Subscription information

Volume 150 (12 issues) will appear in 1991. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: approx. US $ 1060.00 (single issue price approx. $ 102.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to:
Springer-Verlag New York Inc.
Service Center Secaucus
44 Hartz Way
Secaucus, NJ 07094, USA
Tel. (201) 348-4033
Telex 023125994
FAX (201) 348-4505

All other countries. Annual subscription rate: DM 1598.00 plus carriage charges; Federal Republic of Germany: DM 27.61 incl. value added tax; all other countries: DM 60.60 except for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 125.40, India DM 96.60, Australia/New Zealand DM 141.00. Airmail delivery to all other countries is available upon request. Volume price: DM 1598.00, single issue price: DM 159.80 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag
Heidelberger Platz 3, 1000 Berlin 33, FRG
Tel. (0)30/8207-0, Telex 183319
FAX (0)30/8214091

BMJ JOURNALS

CALL FOR PAPERS

Quality in Health Care

EDITOR: **FIONA MOSS**
AUDIT SPECIALIST & RESPIRATORY PHYSICIAN

ASSOCIATE EDITORS: **Steve Nixon**, Surgeon, **Richard Baker**, GP, **Michael Maresh**, Obstetrician
Alison Kitson, Director of RCN Standards of Care Project
Richard Thomson, Public Health and **Chris West**, District General Manager

QUALITY IN HEALTH CARE is a new quarterly journal being launched in March 1992, by the BMJ to reflect and report initiatives to improve quality of health care, from **everybody** involved in health care.

The journal aims to monitor:

- **The relationship between clinical and medical audit and quality assurance programmes**
- **The development of clinical and medical audit as local activities and as larger national initiatives**
- **The integration of medical audit into medical practice**
- **The impact of medical and clinical audit on postgraduate and undergraduate training and education**
- **The relationship between management and quality initiatives**

The editorial board includes, clinicians from a variety of specialties, together with representatives from management, nursing, other health care professions, quality assurance programmes, public health and medical education.

RESEARCH AREAS

- **The development and testing of quality measures**
- **The development of outcome measures**
- **Studies on the appropriateness and effectiveness of medical and other clinical interventions**
- **Commissioned articles will include critical overviews of evidence on which medical and other clinical interventions are based. Opposing views will be sought and debated.**

SUBMISSION

Papers should be submitted, in accordance with Instructions to Authors as set out in the BMJ, to:

Fiona Moss, Editor,
Quality in Health Care,
North West Thames Regional Health Authority, 40 Eastbourne Terrace,
Paddington, London W2 3QR.
Telephone: 071 262 8011 ext. 3098
Fax: 071 258 0530

To receive more information and a sample copy complete the form below:

Order Form

QUALITY IN HEALTH CARE
PUBLICATION: Quarterly
ISSN: 0963-8172
Please tick

☐ Please send me more information
☐ Please send me *Instructions to Authors*
☐ Please send me a sample copy

Signature _____
Name *(Capitals)* _____
Address _____
_____
_____
_____ **Date** _____

Send orders to: **British Medical Journal, BMA House, Tavistock Square, London. WC1H 9JR.**



NovoPen® II

Already a design award winner,[1] NovoPen II has recently received even more attention to detail. The latest model incorporates an easy grip on the dosage dial and a smoother action on the locking ring - a safety feature unique to NovoPen II. The stylish new appearance completes the latest design improvements making NovoPen II even better than before.

PenMix® Penfill® cartridges

Biphasic Isophane Insulin Injection, Human Insulin (pyr).

The first premixed insulin in a Penfill was PenMix 30/70 Penfill, in a ratio well suited to the majority of diabetics using premixed insulins.



The introduction of four additional mixtures makes PenMix® Penfill® the widest range of premixed insulins available in cartridges, and means that even more diabetics could be using NovoPen II.









New NovoFine® needles

The new NovoFine needles for NovoPen II are very fine 28-gauge needles for a virtually painless injection.[2]

NOVOPEN® II FOR MIXTURES TOO

NOVO NORDISK A/S
Copenhagen, Denmark

Further information is available from:
NOVO NORDISK PHARMACEUTICALS LTD
Novo Nordisk House, Broadfield Park,
Brighton Road, Pease Pottage, Crawley,
West Sussex RH11 9RT.
Telephone: (0293) 613555.

Free supplies of NovoPen available on request.
Dial 100 and ask for Freephone Novo Nordisk insulin.

Abbreviated Prescribing Information: PenMix® 10/90 Penfill®, PenMix® 20/80 Penfill®, PenMix® 30/70 Penfill®, PenMix® 40/60 Penfill®, PenMix® 50/50 Penfill®, 100iu/ml (Biphasic Isophane Insulin Injection), Human Insulin (pyr). **Indications:** The treatment of insulin-requiring diabetics. **Dosage and Administration:** The dosage is determined by the physician according to the needs of the patient. Given by subcutaneous injection and intended for use in the NovoPen and NovoPen II injection devices only. (See instructions for use of devices). Resuspend before use by agitating up and down. **Contra-indications:** Hypoglycaemia. **Precautions:** Injection of PenMix Penfill should be followed by a meal within 30 minutes of administration. A dosage reduction may be required on transfer from bovine or mixed species insulin. Reduction of early warning symptoms for hypoglycaemia may be seen upon tightening control and has been reported by a few patients on transfer from animal source to human insulin. Beta blockers, MAOIs and alcohol may enhance hypoglycaemic effect of insulin. Corticosteroids, thyroid hormones, oral contraceptives may increase insulin requirements. **Use in pregnancy:** Insulin requirements usually fall during the first trimester and increase during second and third trimester. **Side-effects:** Lipodystrophy, insulin resistance and hypersensitivity are rarely reported with human insulin. **Product Licence Numbers and Basic NHS Price:** PenMix 10/90 Penfill PL4668/0032, PenMix 20/80 Penfill PL4668/0033, PenMix 30/70 Penfill PL4668/[illegible], PenMix 40/60 Penfill PL4668/0034, PenMix 50/50 Penfill PL4668/[illegible]; 5x1.5ml cartridges £[illegible]. **Product Licence Holder:** Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Denmark. Further information is available on request from: Novo Nordisk Pharmaceuticals Ltd, Novo Nordisk House, Broadfield Park, Brighton Road, Pease Pottage, Crawley, West Sussex RH11 9RT. Telephone: (0293) 613555.

References: 1. 1990 BBC Design Award.
2. Chantelau E et al. BMJ 1991; 303: 26-27.

NP 01/92 January 92